enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Luspatercept - Wikipedia

    en.wikipedia.org/wiki/Luspatercept

    Luspatercept is indicated for the treatment of adults with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

  3. Myelodysplastic syndrome - Wikipedia

    en.wikipedia.org/wiki/Myelodysplastic_syndrome

    Whereas high risk MDS is associated with a life expectancy of less than 3 years. [ 36 ] Stem-cell transplantation offers possible cure, with survival rates of 50% at 3 years, although older patients do poorly.

  4. International Prognostic Scoring System - Wikipedia

    en.wikipedia.org/wiki/International_Prognostic...

    The International Prognostic Scoring System (IPSS), originally published in 1997, is used by many doctors to help assess the severity of a patient's myelodysplastic syndrome (MDS). Based on the IPSS score, the patient's history, and the physician's own personal observations, the physician will design a treatment plan to address the MDS.

  5. Osteoporosis - Wikipedia

    en.wikipedia.org/wiki/Osteoporosis

    The US National Osteoporosis Foundation recommends pharmacologic treatment for patients with hip or spine fracture thought to be related to osteoporosis, those with BMD 2.5 SD or more below the young normal mean (T-score -2.5 or below), and those with BMD between 1 and 2.5 SD below normal mean whose 10-year risk, using FRAX, for hip fracture is ...

  6. Chronic myelomonocytic leukemia - Wikipedia

    en.wikipedia.org/wiki/Chronic_myelomonocytic...

    A score of 0 indicates a low risk group' 1-2 indicates an intermediate risk group and 3-4 indicates a high risk group. The cumulative 2 year survival of scores 0, 1-2 and 3-4 is 91%, 52% and 9%; and risk of AML transformation is 0%, 19% and 54% respectively. [10]

  7. Trabecular bone score - Wikipedia

    en.wikipedia.org/wiki/Trabecular_bone_score

    The trabecular bone score is a measure of bone texture correlated with bone microarchitecture and a marker for the risk of osteoporosis. Introduced in 2008, [1] its main projected use is alongside measures of bone density in better predicting fracture risk in people with metabolic bone problems.

  8. Acute myeloid leukemia - Wikipedia

    en.wikipedia.org/wiki/Acute_myeloid_leukemia

    About half of people with AML have "normal" cytogenetics; they fall into an intermediate risk group. A number of other cytogenetic abnormalities are known to associate with a poor prognosis and a high risk of relapse after treatment. [78] [79] [80] A large number of molecular alterations are under study for their prognostic impact in AML.

  9. Thalassemia - Wikipedia

    en.wikipedia.org/wiki/Thalassemia

    Luspatercept is a drug used to treat anemia in adults with β-thalassemia, it can improve the maturation of red blood cells and reduce the need for frequent blood transfusions. It is administered by injection every three weeks. Luspatercept was authorised for use in the US in 2019 and by the European Medicines Agency in 2020. [77]

  1. Related searches luspatercept high risk mds prognosis mayo clinic treatment for osteoporosis

    what is luspaterceptipss m prognosis
    luspatercept uses